Powered by HealthTechMovers.com
We added 2 stocks to our Healthcare & Biotech Stock Watchlist today because they are receiving Bullish Sentiment from investors and financial bloggers.
In addition, they are generating positive media buzz and/or have insider trading signals which came to our attention. This list below is subject to change on a daily basis, so please be sure you subscribe to our email newsletter.
MoonLake Immunotherapeutics, MLTX
Summary: MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON.
- Last Price: $57.40
- Price Change: -$0.24, -0.42%
- Yearly Gain: 620.50%
- Market Cap: $3.08B
- P/E Ratio: -55.337
Here are 3rd party ratings for MLTX:
- TipRanks.com: Strong Buy
- TradingView.com: buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 37% (94 out of 252)
What is the sentiment on the street regarding MoonLake Immunotherapeutics ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Very Positive
- Hedge Fund signal: Neutral
If you are interested in MLTX or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on MLTX before you decide to make any investment.
Click here for chart >>
Inozyme Pharma, INZY
Summary: Inozyme Pharma Inc. is a biopharmaceutical company. It engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue and skeleton diseases. The company's product candidate consist INZ-701, which is in clinical stage. Inozyme Pharma Inc. is based in Boston, Massachusetts.
- Last Price: $4.38
- Price Change: $0.10, 2.34%
- Yearly Gain: 33.33%
- Market Cap: $264.20M
- P/E Ratio: -2.709
Here are 3rd party ratings for INZY:
- TipRanks.com: Strong Buy
- TradingView.com: sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Weak sell
- Zacks.com: Hold, Top 37% (94 out of 252)
What is the sentiment on the street regarding Inozyme Pharma ? (Current ratings compiled by TipRanks.com)
- News Sentiment: Very Bullish
- Blogger Consensus: Bullish
- Media Buzz: Medium
- Insider Signal: Positive
- Investor Sentiment: Positive
- Hedge Fund signal: Neutral
If you are interested in INZY or any stocks within the Healthcare sector, you might want to click here and check out this report. The stock market is extremely volatile, and you need to do your own research on INZY before you decide to make any investment.
Click here for chart >>
Thanks for reading!
